BMY250411P61000
- 9.35
- 0.000.00%
Bristol-Myers Squibb Newsroom
Earnings Week Ahead: TSLA, GOOG, GE, BA, PG, PEP, ABBV, V, T, AAL, LUV, INTC, IBM, and More
Earnings Preview: BMY to Report Financial Results on April 24
Bristol-Myers Squibb (NYSE:BMY) Gains FDA Approval To Simplify Camzyos Monitoring Process
Catalyst Watch: Spotlight on Tesla, Alphabet Earnings, AACR Drug Data, and Global PMI Reports
Express News | U.S. Food and Drug Administration Updates Camzyos® (Mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
U.S. Food and Drug Administration Updates CAMZYOS (Mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
BofA Securities Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Cuts Target Price to $58
Express News | Bristol-Myers Squibb Co : BofA Global Research Cuts Price Objective to $58 From $63
Is Bristol-Myers Squibb Company (BMY) The Dirt Cheap Stock To Invest In Now?
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Lyft Gains With the FreeNow Acquisition Seen Opening up Market Share Opportunities in Europe
Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and LENZ Therapeutics (LENZ)
Trump Targets Medicare Price Negotiations in New Executive Order
Morgan Stanley Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $36
BMO Capital Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $61
Citi Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $55
Why US Pharma Giant Bristol Myers Squibb Stock Trading Lower On Tuesday?
Express News | Bristol-Myers Squibb Shares Are Trading Lower After the Company Announced Its Phase 3 ODYSSEY-HCM Trial Did Not Meet Its Dual Primary Endpoints
Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy for Long Term Growth?
Sector Update: Health Care Stocks Lower to Flat Premarket Tuesday